359 related articles for article (PubMed ID: 9177525)
1. Clinical application of a new monoclonal antibody (19B7) against PIVKA-II in the diagnosis of hepatocellular carcinoma and pancreatobiliary malignancies.
Nakao A; Taniguchi K; Inoue S; Takeda S; Harada A; Nonami T; Watanabe K; Takagi H
Am J Gastroenterol; 1997 Jun; 92(6):1031-4. PubMed ID: 9177525
[TBL] [Abstract][Full Text] [Related]
2. PIVKA-II during perioperative period in patients with hepato-biliary-pancreatic diseases.
Kanazumi N; Takeda S; Inoue S; Ohshima K; Sugimoto H; Kaneko T; Watanabe K; Nakao A
Hepatogastroenterology; 2000; 47(36):1695-9. PubMed ID: 11149034
[TBL] [Abstract][Full Text] [Related]
3. [Clinical usefulness of plasma PIVKA-II assay and its limitations in patients with hepatocellular carcinoma].
Fujiyama S; Morishita T; Shibata J; Sato T
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-1):1129-38. PubMed ID: 2471453
[TBL] [Abstract][Full Text] [Related]
4. [Evaluation of plasma PIVKA-II as a new marker for hepatocellular carcinoma].
Tada H; Kagawa K; Hikita H; Takeuchi T; Ohta Y; Fukui S; Shintani H; Deguchi T; Okanoue T; Takino T
Gan No Rinsho; 1989 Apr; 35(5):564-70. PubMed ID: 2469809
[TBL] [Abstract][Full Text] [Related]
5. Sensitive measurement of serum abnormal prothrombin (PIVKA-II) as a marker of hepatocellular carcinoma.
Tanaka Y; Kashiwagi T; Tsutsumi H; Nagasawa M; Toyama T; Ozaki S; Naito M; Ishibashi K; Azuma M
Hepatogastroenterology; 1999; 46(28):2464-8. PubMed ID: 10522021
[TBL] [Abstract][Full Text] [Related]
6. Clinical evaluation of plasma abnormal prothrombin (PIVKA-II) in patients with hepatocellular carcinoma.
Fujiyama S; Morishita T; Sagara K; Sato T; Motohara K; Matsuda I
Hepatogastroenterology; 1986 Oct; 33(5):201-5. PubMed ID: 2433199
[TBL] [Abstract][Full Text] [Related]
7. [Clinical evaluation of PIVKA-II in patients with hepatocellular carcinoma. Detection of PIVKA-II by EIA using anti-PIVKA-II monoclonal antibody].
Ohtani M; Ido K; Kawamoto C; Kimura K
Rinsho Byori; 1989 Apr; 37(4):405-9. PubMed ID: 2545953
[No Abstract] [Full Text] [Related]
8. Usefulness of determining a protein induced by vitamin K absence in detection of hepatocellular carcinoma.
Cui R; Wang B; Ding H; Shen H; Li Y; Chen X
Chin Med J (Engl); 2002 Jan; 115(1):42-5. PubMed ID: 11930656
[TBL] [Abstract][Full Text] [Related]
9. The des-gamma-carboxy prothrombin index is a new prognostic indicator for hepatocellular carcinoma.
Nagaoka S; Yatsuhashi H; Hamada H; Yano K; Matsumoto T; Daikoku M; Arisawa K; Ishibashi H; Koga M; Sata M; Yano M
Cancer; 2003 Dec; 98(12):2671-7. PubMed ID: 14669288
[TBL] [Abstract][Full Text] [Related]
10. [Development of highly sensitive assay for detection of low serum level of PIVKA-II and its clinical usefulness].
Sakizono K; Oita T; Kuroda M; Kasakura S
Rinsho Byori; 1996 Sep; 44(9):871-6. PubMed ID: 8911073
[TBL] [Abstract][Full Text] [Related]
11. Usefulness of simultaneous determination of alpha-fetoprotein and des-gamma-carboxy prothrombin in hepatocellular carcinoma.
Nakao A; Taniguchi K; Inoue S; Harada A; Nonami T; Watanabe K; Takagi H
Semin Surg Oncol; 1996; 12(3):160-3. PubMed ID: 8727604
[TBL] [Abstract][Full Text] [Related]
12. Acarboxy prothrombin (PIVKA II) as a tumour marker for hepatocellular carcinoma and other liver diseases.
Mohamedein A; Yousif-Kadaru AG; Ahmed SA; Saida H; Zaki ZA; Eldin ; Fedail SS
East Afr Med J; 1995 Sep; 72(9):584-7. PubMed ID: 7498046
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical study of protein induced by vitamin K absence or antagonist II in hepatocellular carcinoma.
Ajisaka H; Shimizu K; Miwa K
J Surg Oncol; 2003 Oct; 84(2):89-93. PubMed ID: 14502782
[TBL] [Abstract][Full Text] [Related]
14. [Clinical evaluation of PIVKA-II as a marker of hepatocellular carcinoma].
Arima K; Kodama T; Suga M; Sakamoto H; Ohe Y; Yachi A
Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 2):3049-52. PubMed ID: 2476968
[TBL] [Abstract][Full Text] [Related]
15. [Optimal cut-off value of PIVKA-II for diagnosis of hepatocellular carcinoma--using ROC curve].
Kim MJ; Bae KW; Seo PJ; Jeong IK; Kim JH; Lee BH; Bang KT; Kim DW; Song IH
Korean J Hepatol; 2006 Sep; 12(3):404-11. PubMed ID: 16998292
[TBL] [Abstract][Full Text] [Related]
16. Clinical evaluation of plasma abnormal prothrombin (des-gamma-carboxy prothrombin) in hepatobiliary malignancies and other diseases.
Nakao A; Suzuki Y; Isshiki K; Kimura Y; Takeda S; Kishimoto W; Nonami T; Harada A; Takagi H
Am J Gastroenterol; 1991 Jan; 86(1):62-6. PubMed ID: 1702578
[TBL] [Abstract][Full Text] [Related]
17. Use of serum PIVKA-II (DCP) determination for differentiation between benign and malignant liver diseases.
Lamerz R; Runge M; Stieber P; Meissner E
Anticancer Res; 1999; 19(4A):2489-93. PubMed ID: 10470180
[TBL] [Abstract][Full Text] [Related]
18. [A staining method of PIVKA-II by an indirect immunoenzyme technic].
Tanimoto K; Onji M; Nadano S; Kumon I; Michitaka K; Horiike N; Ohta Y
Rinsho Byori; 1989 Oct; 37(10):1139-42. PubMed ID: 2481050
[TBL] [Abstract][Full Text] [Related]
19. [Fundamental studies, reference values, and clinical evaluation of abnormal prothrombin PIVKA-II assay using monoclonal antibody (E-1023)].
Sakurabayashi I; Kawai T; Omizo R; Hattori N; Ishii M
Rinsho Byori; 1988 Dec; 36(12):1407-12. PubMed ID: 2854864
[No Abstract] [Full Text] [Related]
20. Measurement of serum levels of des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma by a revised enzyme immunoassay kit with increased sensitivity.
Okuda H; Nakanishi T; Takatsu K; Saito A; Hayashi N; Watanabe K; Magario N; Yokoo T; Naraki T
Cancer; 1999 Feb; 85(4):812-8. PubMed ID: 10091758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
